 DUBLIN, Ireland and CHICAGO, Sept. 07, 2022 GLOBE NEWSWIRE -- Iterum Therapeutics plc Nasdaq: ITRM the Company, a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that Corey Fishman, Chief Executive Officer, and Judy Matthews, Chief Financial Officer, will provide a company overview and business update at the H.C. Wainwright 24th Annual Hybrid Global Investment Conference at 12:00pmET on Wednesday, September 14, 2022. Management will also host investor meetings on September 13-14, 2022. 